Batten Disease
Researchers recently have found that male and female brains show different responses as the Batten Disease progresses and have found a model of the disease that could transform future treatments.
About Batten Disease
Batten disease, also known as neuronal ceroid lipofuscinosis (NCL), is a group of rare, fatal, inherited neurodegenerative disorders that primarily affect children. It is caused by genetic mutations that lead to the buildup of fatty substances and proteins called lipopigments in the body's cells, particularly in the brain and eyes, which causes cell damage and death.
Symptoms
Symptoms typically begin in childhood, although the age of onset and rate of progression vary widely depending on the specific genetic type. Common signs include:
- Progressive vision loss, often an early sign that eventually leads to blindness.
- Seizures (epilepsy) that can become difficult to control with medication.
- Decline in motor skills, leading to clumsiness, an unsteady walk (ataxia), loss of coordination, and eventual paralysis.
- Cognitive impairment and dementia, including learning difficulties, memory loss, and speech problems.
- Personality and behavior changes, such as mood swings, anxiety, aggression, and hallucinations.
- Muscle involvement, including spasms (myoclonus), stiffness (spasticity), and weakness.
- Heart problems, such as abnormal heart rhythms, in teenagers and young adults with some forms.
Causes and Genetics
Batten disease is typically an autosomal recessive disorder, meaning a child must inherit a copy of a mutated CLN gene from both parents to develop the condition. Parents who are carriers (have one copy of the mutated gene) usually do not show symptoms themselves. There are at least 13 different gene mutations identified (CLN1 through CLN14) that cause the various forms of the disease. The specific gene affected determines the form and the typical age of onset. The adult form, CLN4, can be inherited in an autosomal dominant manner.
Diagnosis
Diagnosis typically involves a combination of clinical evaluation, family history, and various tests:
- Genetic testing is the most reliable way to confirm the diagnosis and identify the specific type.
- Eye exams to detect retinal degeneration and optic nerve changes.
- Blood or urine tests to look for specific abnormalities, such as the characteristic lipopigment deposits in white blood cells.
- Brain imaging (MRI or CT scans) to check for brain atrophy.
- Electroencephalogram (EEG) to record the brain's electrical activity and identify seizures.
Treatment and Prognosis
- There is currently no cure for most forms of Batten disease, and most types are fatal, generally by the late teens or twenties. Treatment focuses on managing symptoms and improving the patient's quality of life.
- Symptom management includes anticonvulsant medications for seizures, physical and occupational therapy to maintain motor skills, and counseling for behavioral and emotional challenges.
- Enzyme replacement therapy with the medication cerliponase alfa (Brineura®) is an FDA-approved treatment for children with the CLN2 type, which slows the progression of motor function loss but does not reverse symptoms or affect vision loss.
- Ongoing research is exploring promising avenues such as gene therapy and stem cell transplants.
- The prognosis is generally poor, with affected individuals losing the ability to walk, speak, or see and requiring round-the-clock care in the final stages of the disease. Adult-onset forms may progress more slowly and may not affect life expectancy.
-
Download Pdf
